<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736928</url>
  </required_header>
  <id_info>
    <org_study_id>43USD1801</org_study_id>
    <nct_id>NCT03736928</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines</brief_title>
  <official_title>A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA&#xD;
      treatment for glabellar lines&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Actual">August 20, 2020</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Composite Responders at Month 1</measure>
    <time_frame>Month 1 after treatment</time_frame>
    <description>composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grade improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular single treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbobotulinumtoxinA dose level 1 or 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular single treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbobotulinumtoxinA dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular single treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbobotulinumtoxinA dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular single treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AbobotulinumtoxinA dose level 1 or 2</intervention_name>
    <description>Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines</description>
    <arm_group_label>AbobotulinumtoxinA dose level 1 or 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AbobotulinumtoxinA dose 3</intervention_name>
    <description>Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines</description>
    <arm_group_label>AbobotulinumtoxinA dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AbobotulinumtoxinA dose 4</intervention_name>
    <description>Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines</description>
    <arm_group_label>AbobotulinumtoxinA dose level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe glabellar lines at maximum frown as assessed by the Investigator&#xD;
             using a photographic scale&#xD;
&#xD;
          -  Moderate to severe glabellar lines at maximum frown as assessed by the subject using a&#xD;
             static categorical scale&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Botulinum toxin treatment in the face within 9 months prior to study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Manhattan Beach</city>
        <state>California</state>
        <zip>90266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <results_first_submitted>December 21, 2020</results_first_submitted>
  <results_first_submitted_qc>January 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2021</results_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03736928/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03736928/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>401 subjects were randomized, and 399 subjects received study product. Two (2) of the 401 randomized subjects did not receive study product due to hypertension that was identified pre-treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose group 3 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 3: treatment of glabellar facial lines</description>
        </group>
        <group group_id="P4">
          <title>Dose Level 4 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose group 4 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 4: treatment of glabellar facial lines</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Subjects randomized to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose level 1 AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 2 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose level 2 AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
        </group>
        <group group_id="B3">
          <title>Dose Level 3 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose group 3 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 3: treatment of glabellar facial lines</description>
        </group>
        <group group_id="B4">
          <title>Dose Level 4 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose group 4 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 4: treatment of glabellar facial lines</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Subjects randomized to placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="78"/>
            <count group_id="B6" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="9.54"/>
                    <measurement group_id="B2" value="50.2" spread="10.33"/>
                    <measurement group_id="B3" value="46.3" spread="11.52"/>
                    <measurement group_id="B4" value="48.4" spread="10.22"/>
                    <measurement group_id="B5" value="47.6" spread="11.5"/>
                    <measurement group_id="B6" value="48.4" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="352"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type (FST)</title>
          <description>FST I: white; very fair; red or blond hair; blue eyes; freckles. always burns, never tans.&#xD;
FST II: white; fair; red or blond hair; blue, hazel or green eyes. usually burns, tans with difficulty.&#xD;
FST III: cream white; fair with any eye or hair color; very common. sometimes mild burn, gradually tans.&#xD;
FST IV: brown; typical Mediterranean Caucasian skin. rarely burns, tans with ease.&#xD;
FST V: dark brown; Middle Eastern skin types. very rarely burns, tans very easily.&#xD;
FST VI: Skin color - black. Skin Characteristics - never burns, tans very easily.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FST I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FST II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FST III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FST IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FST V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FST VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Composite Responders at Month 1</title>
        <description>composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grade improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)</description>
        <time_frame>Month 1 after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 AbobotulinumtoxinA</title>
            <description>Subjects randomized (4:1) to dose level 1 AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 AbobotulinumtoxinA</title>
            <description>Subjects randomized (4:1) to dose level 2 AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 AbobotulinumtoxinA</title>
            <description>Subjects randomized (4:1) to dose group 3 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 3: treatment of glabellar facial lines</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 4 AbobotulinumtoxinA</title>
            <description>Subjects randomized (4:1) to dose group 4 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 4: treatment of glabellar facial lines</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Subjects randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Composite Responders at Month 1</title>
          <description>composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grade improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
        </group>
        <group group_id="E2">
          <title>Dose Level 2 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to AbobotulinumtoxinA or placebo&#xD;
AbobotulinumtoxinA dose 1/2: treatment of glabellar facial lines&#xD;
placebo: treatment of glabellar facial lines</description>
        </group>
        <group group_id="E3">
          <title>Dose Level 3 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose group 3 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 3: treatment of glabellar facial lines</description>
        </group>
        <group group_id="E4">
          <title>Dose Level 4 AbobotulinumtoxinA</title>
          <description>Subjects randomized (4:1) to dose group 4 AbobotulinumtoxinA or placebo&#xD;
placebo: treatment of glabellar facial lines&#xD;
AbobotulinumtoxinA dose 4: treatment of glabellar facial lines</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Subjects randomized to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiplegic migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>QMedAB</organization>
      <phone>(817) 961-5000</phone>
      <email>aestheticclinicaltrials@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

